bevacizumab
Sign in to saveAlso known as 12-IGG1, RG-435, antiVEGF, R-435, Rhumab-VEGF, Avastin
Bevacizumab, sold under the brand name Avastin among others, is a monoclonal antibody medication used to treat a number of types of cancers and a specific eye disease. For cancer, it is given by slow injection into a vein (intravenous) and used for colon cancer, lung cancer, ovarian cancer, glioblastoma, hepatocellular carcinoma, and renal-cell carcinoma. In many of these diseases it is used as a first-line therapy. For age-related macular degeneration it is given by injection into the eye (intravitreal).
Key facts
- Drug.Verifiedfields
- changed
- Drug.Watchedfields
- changed
- Drug.verifiedrevid
- 477165031
- Drug.type
- mab
- Drug.mab_type
- mab
- Drug.source
- zu/o
- Drug.target
- VEGF-A
- Drug.tradename
- Avastin, others
- Drug.MedlinePlus
- a607001
- Drug.DailyMedID
- Bevacizumab
- Drug.pregnancy_AU
- D
- Drug.routes_of_administration
- Intravenous, intravitreal
- Drug.ATC_prefix
- L01
- Drug.ATC_suffix
- FG01
- Drug.biosimilars
- bevacizumab-adcd, bevacizumab-awwb, bevacizumab-bvzr, bevacizumab-maly, bevacizumab-nwgd, bevacizumab-tnjn, Abevmy, Alymsys, Avzivi, Aybintio, Bambevi, Bevacip, Bevaciptin, Equidacent, Jobevne Mvasi, Onbevzi, Oyavas, Vegzelma, Zirabev
- Drug.legal_AU
- S4
- Drug.legal_CA
- Rx-only
- Drug.legal_CA_comment
- / Schedule D
via Wikipedia infobox
Research
27,333 papers- Bevacizumab (Avastin®) in cancer treatment: A review of 15 years of clinical experience and future outlook.Cancer treatment reviews · 2020
- Optimal bevacizumab treatment strategy in advanced ovarian cancer: A review.Cancer treatment reviews · 2025
- SB8: A Bevacizumab Biosimilar.Targeted oncology · 2020
- MYL-1402O: A Bevacizumab Biosimilar.Targeted oncology · 2022
- Adjuvant Intralesional Bevacizumab in Pediatric and Adult Populations With Recurrent Respiratory Papillomatosis: A Systematic Review.The Annals of otology, rhinology, and laryngology · 2024
via PubMed
~22 min read
Encyclopedic overview
23 sectionsContents
- Medical uses
- Colorectal cancer
- Lung cancer
- Breast cancer
- Kidney cancer
- Brain cancers
- Macular degeneration
- Ovarian cancer
- Cervical cancer
- Adverse effects
- Mechanism of action
- Chemistry
- History
- Approval
- Society and culture
- Use for macular degeneration
- Breast cancer approval
- Counterfeit
- Biosimilars
- Research
- References
- Further reading
- External links
Bevacizumab, sold under the brand name Avastin among others, is a monoclonal antibody medication used to treat a number of types of cancers and a specific eye disease. For cancer, it is given by slow injection into a vein (intravenous) and used for colon cancer, lung cancer, ovarian cancer, glioblastoma, hepatocellular carcinoma, and renal-cell carcinoma. In many of these diseases it is used as a first-line therapy. For age-related macular degeneration it is given by injection into the eye (intravitreal).
Common side effects when used for cancer include nose bleeds, headache, high blood pressure, and rash. Other severe side effects include gastrointestinal perforation, bleeding, allergic reactions, blood clots, and an increased risk of infection. When used for eye disease side effects can include vision loss and retinal detachment. Bevacizumab is a monoclonal antibody that functions as an angiogenesis inhibitor. It works by slowing the growth of new blood vessels by inhibiting vascular endothelial growth factor A (VEGF-A), in other words anti–VEGF therapy.
Excerpted from Wikipedia’s “bevacizumab” article, available under the CC BY-SA 4.0 licence.